Depemokimab for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new asthma treatment called Depemokimab. Researchers aim to observe how the body absorbs and reacts to the drug when administered through either a special device or an autoinjector. The trial seeks generally healthy participants with no major health issues or drug allergies. Those who are healthy and interested in the development of new treatments may find this opportunity suitable. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have any health conditions or are taking medications that could affect the study, you might not be eligible to participate.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research has shown that depemokimab is generally safe for humans. In earlier studies with healthy adults, depemokimab proved about 29 times more effective than similar treatments and remained in the body longer, often indicating safety. Another study involving individuals with asthma or chronic sinus issues with nasal polyps found it safe when administered twice a year. Although these results are preliminary, they suggest depemokimab is safe for humans thus far. Prospective participants should consult a healthcare professional before joining a trial.12345
Why are researchers excited about this trial?
Unlike the standard asthma treatments, which often include inhaled corticosteroids and bronchodilators, depemokimab is unique because it is administered via a single subcutaneous dose (SSD) or an autoinjector, offering convenience and potential for better adherence. Researchers are excited about depemokimab because it targets a different pathway in the immune system, potentially leading to more effective control of asthma symptoms. This novel approach could provide relief for patients who don't respond well to conventional therapies.
What evidence suggests that Depemokimab might be an effective treatment for asthma?
Research has shown that Depemokimab can significantly benefit individuals with severe asthma, particularly those with elevated eosinophils, a specific type of white blood cell. Studies have found that Depemokimab can reduce severe asthma attacks by 54%. This treatment targets a protein called IL-5, which contributes to inflammation. In this trial, participants will receive Depemokimab either via an SSD or an autoinjector. As a long-lasting medication, Depemokimab remains in the body longer, enhancing its effectiveness in alleviating asthma symptoms. Its potency and extended presence in the body make it a promising option for asthma relief.36789
Who Is on the Research Team?
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Are You a Good Fit for This Trial?
Healthy adults who weigh at least 50 kg with a BMI of 19-30 can join. They must have no significant allergies, especially to monoclonal antibodies or biologics, and no history of severe drug allergies or substance abuse. Women able to get pregnant should use effective birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of Depemokimab via either a safety syringe device or an autoinjector
Follow-up
Participants are monitored for safety, tolerability, and immunogenicity after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Depemokimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
PPD DEVELOPMENT, LP
Industry Sponsor
David Simmons
PPD DEVELOPMENT, LP
Chief Executive Officer since 2012
BSc in Applied Science from Georgia Institute of Technology
Martina Flammer
PPD DEVELOPMENT, LP
Chief Medical Officer since 2024
MD
PPD Development, LP
Industry Sponsor
PPD
Industry Sponsor
Dr. Austin Smith
PPD
Chief Medical Officer since 2020
Doctor of Medicine from the Royal College of Surgeons in Ireland
David Simmons
PPD
Chief Executive Officer since 2012
Bachelor’s degree in Applied Mathematics and Industrial Management from Carnegie Mellon University